e1r

E1R is a positive sigma-1 receptor (Sig1R PAM) allosteric modulator. It has a cognition-enhancing activity.

(2R,3S)-E1R (Compound 2c) is an enantiomer of E1R. (2R,3R)-E1R is a sigma-1 receptor positive allosteric modulator for treating cognition and memory disorders.

(2S,3S)-E1R (Compound 2d) is an enantiomer of (2R,3R)-E1R, a sigma-1 receptor positive allosteric modulator for the treatment of cognition/memory disorders.

(2R,3R)-E1R is an enantiomer of E1R. (2R,3R)-E1R is a sigma-1 receptor positive allosteric modulator for the treatment of cognition/memory disorders.

(Rac)-E1R is the racemate of E1R. (Rac)-E1R is a sigma-1 receptor positive allosteric (Sig1R PAM) modulator of for the treatment of cognition/memory disorders.

4E1RCat is a dual inhibitor of eIF4E:eIF4 g and eIF4E:4E-BP1 interaction. And it inhibits the binding of eIF4 g to eIF4E with IC50 of 3.2 μM.

4E1rcat 17d features a core structure of (E)-3-(2-furanmethylmethylene)-2-pyrrolidone, and its analog 4E1rcat blocked the interactions between ATG5-ATG16L1 and ATG5-TECAIR in in vitro binding assays with IC50 values of 1.1 μM and 1.7 μM, respectively.

4E1rcat analogue 1 has a core structure of (E)-3-(2-furanmethylmethylene)-2-pyrrolidone, and its analog 4E1rcat blocked the interactions between ATG5-ATG16L1 and ATG5-TECAIR in in vitro binding assays with IC50 values of 1.1 μM and 1.7 μM, respectively.

4E1rcat analogue 2 has a core structure of (E)-3-(2-furylmethylene)-2-pyrrolidinone, and its analog 4E1rcat blocks the interactions between ATG5–ATG16L1 and ATG5–TECAIR in in vitro binding assays, with IC₅₀ values of 1.1 μM and 1.7 μM, respectively.

4E1rcat analogue 3 has a (E)-3-(2-furanylmethylene)-2-pyrrolidinone core structure, and its analog 4E1rcat blocks the interactions between ATG5-ATG16L1 and ATG5-TECAIR in in vitro binding assays with IC50 values of 1.1 μM and 1.7 μM, respectively.

4E1rcat analogue 4 has an (E)-3-(2-furanmethyl methylene)-2-pyrrolidone core structure. Its analogue 4E1rcat blocked the interaction between ATG5-ATG16L1 and ATG5-TECAIR in the in vitro binding assay, with IC50 values of 1.1 μM and 1.7 μM respectively.

4E1rcat analogue 5 possesses a core structure of (E)-3-(2-furanylmethylene)-2-pyrrolidinone. Its parent compound 4E1rcat blocks the interactions between ATG5-ATG16L1 and ATG5-TECAIR in in vitro binding assays, with IC₅₀ values of 1.1 μM and 1.7 μM, respectively.

4E1rcat 27d (Compound 27d) contains a core structure of (E)-3-(2-furanylmethylene)-2-pyrrolidinone. Its analog 4E1rcat blocks the interactions between ATG5-ATG16L1 and ATG5-TECAIR in in vitro binding assays, with IC₅₀ values of 1.1 μM and 1.7 μM, respectively.

4E1rcat analogue 6 has an (E)-3-(2-furanmethyl methylene)-2-pyrrolidone core structure. Its analogue 4E1rcat blocked the interaction between ATG5-ATG16L1 and ATG5-TECAIR in the in vitro binding assay, with IC50 values of 1.1 μM and 1.7 μM respectively.

4E1rcat analogue 7 possesses an (E)-3-(2-furylmethylene)-2-pyrrolidone core structure. Its analog 4E1rcat blocks the interactions between ATG5-ATG16L1 and ATG5-TECAIR in in vitro binding assays, with IC50 values of 1.1 μM and 1.7 μM, respectively.

4E1rcat analogue 8 has a core structure of (E)-3-(2-furylmethylene)-2-pyrrolidinone, and its analog 4E1rcat blocks the interactions between ATG5–ATG16L1 and ATG5–TECAIR in in vitro binding assays, with IC₅₀ values of 1.1 μM and 1.7 μM, respectively.

4E1rcat analogue 9 has an (E)-3-(2-furylmethylene)-2-pyrrolidone core structure. Its analog 4E1rcat blocks the interactions between ATG5-ATG16L1 and ATG5-TECAIR in in vitro binding assays, with IC50 values of 1.1 μM and 1.7 μM, respectively.

D-F07 is a novel fluorescent IRE-1 RNase inhibitor and a tricyclic chromone with potential anticancer activity.

B I09, an IRE-1 RNase inhibitor with an IC50 of 1230 nM, inhibits splicing of XBP1 mRNA in human WaC3 cells and expression of xbp-1 in LPS-stimulated B cells. B I09 can be used to simulate the defects of XBP-1 in CLL cells., an IRE-1 RNase inhibitor with an IC50 of 1230 nM, inhibits splicing of XBP1 mRNA in human WaC3 cells and expression of xbp-1 in LPS-stimulated B cells. B I09 can be used to simulate the defects of XBP-1 in CLL cells., an IRE-1 RNase inhibitor with an IC50 of 1230 nM, inhibits splicing of XBP1 mRNA in human WaC3 cells and expression of xbp-1 in LPS-stimulated B cells. B I09 can be used to simulate the defects of XBP-1 in CLL cells.

Telmisartan (BIBR 277) is an Angiotensin 2 Receptor Blocker. The mechanism of action of telmisartan is as an Angiotensin 2 Receptor Antagonist.

Azilsartan Medoxomil (TAK-491) is an orally administered angiotensin II receptor type 1 antagonist with IC50 of 0.62 nM, which used in the treatment of adults with essential hypertension.

L162441 is an antagonist of Angiotensin type 1 receptor.

MKC8866 is a selective IRE1 RNase inhibitor (IC50: 0.29 μM in human vitro). MKC8866 inhibits IRE1 RNase in breast cancer cells leading to the decreased production of pro-tumorigenic factors and it can inhibit prostate cancer (PCa) tumor growth.

angiotensin AT1 receptor antagonist